| 摘要 |
Compositions, methods and systems are provided for pulmonary delivery of long-acting muscarinic antagonists and long-acting β2 adrenergic receptor agonists via a metered dose inhaler. In particular embodiments, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium. |
| 主权项 |
1. A method for treating a pulmonary disease or disorder in a patient, wherein the pulmonary disease or disorder is selected from at least one of the group consisting of asthma, COPD, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pulmonary hypertension, and pulmonary inflammation or obstruction resulting from cystic fibrosis, the method comprising:
providing a metered dose inhaler comprising a pharmaceutically acceptable co-suspension, the co-suspension comprising:
a suspension medium consisting essentially of a pharmaceutically acceptable HFA propellant;a plurality of active agent particles comprising a pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate in crystalline form; anda plurality of respirable suspending particles, wherein the plurality of suspending particles are formed separately from and are different particles than the active agent particles and are formed of a dry particulate phospholipid material that is substantially insoluble in the suspension medium; andadministering the co-suspension to the patient by actuating the metered dose inhaler at least once, wherein said administering of the co-suspension composition comprises delivering a dose of 80 μg, or less, of glycopyrrolate per actuation of the metered dose inhaler and results in an increase in forced expiratory volume in one second (FEV1) in the patient of at least 70 mL. |
